These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 22842506)

  • 21. New oral anticoagulants in elderly patients with atrial fibrillation.
    Deedwania PC
    Am J Med; 2013 Apr; 126(4):289-96. PubMed ID: 23369212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Lenchus JD
    Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The need for new oral anticoagulants in clinical practice.
    Hylek EM
    J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):605-9. PubMed ID: 19571764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalizing oral anticoagulant treatment in patients with atrial fibrillation.
    Capranzano P; Miccichè E; D'Urso L; Privitera F; Tamburino C
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):959-73. PubMed ID: 23957907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.
    Salim I; Al Suwaidi J; Ghadban W; Salam AM
    Expert Opin Drug Saf; 2013 Jan; 12(1):53-63. PubMed ID: 23095103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.
    Hylek EM; Skates SJ; Sheehan MA; Singer DE
    N Engl J Med; 1996 Aug; 335(8):540-6. PubMed ID: 8678931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation.
    Mercaldi CJ; Ciarametaro M; Hahn B; Chalissery G; Reynolds MW; Sander SD; Samsa GP; Matchar DB
    Stroke; 2011 Jan; 42(1):112-8. PubMed ID: 21148442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
    Leey JA; McCabe S; Koch JA; Miles TP
    Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?
    Lip GY
    J R Coll Physicians Edinb; 2012; 42 Suppl 18():35-44. PubMed ID: 22518392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: The appropriate use and barriers to oral anticoagulant therapy.
    Partington SL; Abid S; Teo K; Oczkowski W; O'Donnell MJ
    Thromb Res; 2007; 120(5):663-9. PubMed ID: 17434577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.
    You JH
    Pharmacogenet Genomics; 2014 Jan; 24(1):6-14. PubMed ID: 24168919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.
    Sorensen SV; Dewilde S; Singer DE; Goldhaber SZ; Monz BU; Plumb JM
    Am Heart J; 2009 Jun; 157(6):1064-73. PubMed ID: 19464418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of oral anticoagulation among stroke patients with atrial fibrillation in China: the ChinaQUEST (Quality evaluation of stroke care and treatment) registry study.
    Gao Q; Fu X; Wei JW; Chen X; Huang Y; Wang J; Anderson CS; Wong KS;
    Int J Stroke; 2013 Apr; 8(3):150-4. PubMed ID: 22168348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
    Garcia DA
    Thromb Res; 2012 Jan; 129(1):9-16. PubMed ID: 22018997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV; Gage BF
    Circulation; 2011 Jun; 123(22):2562-70. PubMed ID: 21606397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C; Singh BN
    Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.